Amgen's Otezla bags expanded FDA nod in psoriasis; I-Mab CEO hits the exit amid shakeup at Chinese firm
Just a few weeks after Otezla notched a Phase III win and hit all primary and secondary endpoints for a trial in genital psoriasis, Amgen’s blockbuster drug Otezla gets yet another OK from the FDA.
The biotech announced yesterday the FDA approved Otezla (apremilast) for an expanded indication: the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.